Neurocrine Begins Phase 2 Trial of NBI-'567 in Alzheimer Disease
Neurocrine has started a phase 2 study of once-daily NBI-'567 in adults with mild to moderate Alzheimer disease. The trial will assess whether the selective muscarinic agonist can improve cognition.
Neurocrine is now testing NBI-'567, a once-daily selective muscarinic agonist, in adults with mild to moderate Alzheimer disease. The phase 2 study is intended to show whether the drug can improve cognition in this population. The available announcement does not provide trial size, duration, locations, or results, so the central question is whether this mechanism will produce measurable cognitive benefit.
If the phase 2 results suggest cognitive benefit, the trial could affect adults with mild to moderate Alzheimer disease, their families, and caregivers by adding a potential option to discuss with clinicians. It may also shape expectations for muscarinic-targeting drug development. Because this is an early-stage study, broader societal impact would likely depend on later evidence and access.